Spain Viral Vectors Plasmid DNA Manufacturing Market

ID: MRFR/MED/50132-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026
Spain Viral Vectors and Plasmid DNA Manufacturing Market Research Report By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, Infectious Disease), By Application (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research), By Workflow (Upstream Processing, Downstream Processing) and By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) -Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Spain Viral Vectors Plasmid DNA Manufacturing Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)11.99%
2024 Market Size$ 5 Million
2025 Market Size$ 5.66 Million
2035 Market Size$ 17.38 Million

Key Players

Vivebiotech
Genomatica
Vaxine Pty Ltd
Viralgen
Cobra Biologics
Adenoviral Vector
Trends
  • Increased Investment in Biotechnology
  • Regulatory Support for Gene Therapies
  • Collaboration Between Academia and Industry
Opportunities
  • Supportive Regulatory Framework
  • Growing Demand for Gene Therapies
  • Rising Investment in Biotechnology Startups
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Gene Therapy
      2. 4.1.2 Vaccine Development
      3. 4.1.3 Oncology
      4. 4.1.4 Genetic Disorders
      5. 4.1.5 Infectious Diseases
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Pharmaceutical Companies
      2. 4.2.2 Biotechnology Firms
      3. 4.2.3 Research Institutions
      4. 4.2.4 Academic Organizations
    3. 4.3 Healthcare, BY Type of Vector (USD Million)
      1. 4.3.1 Adenoviral Vectors
      2. 4.3.2 Lentiviral Vectors
      3. 4.3.3 Adeno-Associated Viral Vectors
      4. 4.3.4 Retroviral Vectors
    4. 4.4 Healthcare, BY Production Scale (USD Million)
      1. 4.4.1 Small Scale
      2. 4.4.2 Medium Scale
      3. 4.4.3 Large Scale
    5. 4.5 Healthcare, BY Technology (USD Million)
      1. 4.5.1 Transfection
      2. 4.5.2 Electroporation
      3. 4.5.3 Viral Packaging
      4. 4.5.4 Microinjection
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Vivebiotech (ES)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Genomatica (ES)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Vaxine Pty Ltd (ES)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Viralgen (ES)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Cobra Biologics (ES)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Adenoviral Vector (ES)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Virovek (ES)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Biovian (ES)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SPAIN MARKET ANALYSIS BY APPLICATION
    3. 6.3 SPAIN MARKET ANALYSIS BY END USE
    4. 6.4 SPAIN MARKET ANALYSIS BY TYPE OF VECTOR
    5. 6.5 SPAIN MARKET ANALYSIS BY PRODUCTION SCALE
    6. 6.6 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VECTOR, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VECTOR, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY PRODUCTION SCALE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY PRODUCTION SCALE, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VECTOR, 2026-2035 (USD Million)
      4. 7.2.4 BY PRODUCTION SCALE, 2026-2035 (USD Million)
      5. 7.2.5 BY TECHNOLOGY, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Spain Viral Vectors Plasmid DNA Manufacturing Market Segmentation

Spain Viral Vectors Plasmid DNA Manufacturing Market By Application (USD Million, 2026-2035)

  • Gene Therapy
  • Vaccine Development
  • Oncology
  • Genetic Disorders
  • Infectious Diseases

Spain Viral Vectors Plasmid DNA Manufacturing Market By End Use (USD Million, 2026-2035)

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Institutions
  • Academic Organizations

Spain Viral Vectors Plasmid DNA Manufacturing Market By Type of Vector (USD Million, 2026-2035)

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Adeno-Associated Viral Vectors
  • Retroviral Vectors

Spain Viral Vectors Plasmid DNA Manufacturing Market By Production Scale (USD Million, 2026-2035)

  • Small Scale
  • Medium Scale
  • Large Scale

Spain Viral Vectors Plasmid DNA Manufacturing Market By Technology (USD Million, 2026-2035)

  • Transfection
  • Electroporation
  • Viral Packaging
  • Microinjection

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035